401 related articles for article (PubMed ID: 19242664)
1. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
Zhang Z; Schmitt J; Wozel G; Kirch W
Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W
Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372
[TBL] [Abstract][Full Text] [Related]
3. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
6. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
8. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
10. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
Ryan C; Leonardi CL; Krueger JG; Kimball AB; Strober BE; Gordon KB; Langley RG; de Lemos JA; Daoud Y; Blankenship D; Kazi S; Kaplan DH; Friedewald VE; Menter A
JAMA; 2011 Aug; 306(8):864-71. PubMed ID: 21862748
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of TNF-alpha antagonists for plaque-type psoriasis: a systematic review and graphical presentation].
Levy-Roy A; Porcher R; de Fonclare AL; Morel P; Dupuy A
Ann Dermatol Venereol; 2009 Apr; 136(4):315-22. PubMed ID: 19361697
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.
Bansback N; Sizto S; Sun H; Feldman S; Willian MK; Anis A
Dermatology; 2009; 219(3):209-18. PubMed ID: 19657180
[TBL] [Abstract][Full Text] [Related]
13. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
[TBL] [Abstract][Full Text] [Related]
14. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Tanjong Ghogomu E; Tugwell P
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007848. PubMed ID: 19821440
[TBL] [Abstract][Full Text] [Related]
15. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapies for psoriasis. A systematic review.
Boehncke WH; Prinz J; Gottlieb AB
J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
[TBL] [Abstract][Full Text] [Related]
17. Advancements in the treatment of psoriasis: role of biologic agents.
Rich SJ; Bello-Quintero CE
J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
Brunasso AM; Puntoni M; Salvini C; Delfino C; Curcic P; Gulia A; Massone C
Acta Derm Venereol; 2011 Jan; 91(1):44-9. PubMed ID: 21088813
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab for the treatment of psoriasis.
Turner D; Picot J; Cooper K; Loveman E
Health Technol Assess; 2009 Sep; 13 Suppl 2():49-54. PubMed ID: 19804689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]